Ø

Deciaration for Ratent Appl PATENT &

As a below named inventor, I hereby declare trust:

Docket Number: 0509,4830001/KRM/SJB

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled Folylpolyglutamyl Synthetase Gene Transfer T, Enhance Antifolate Drug Sensitivity, the specification of which is attached hereto unless the following box is checked:

was filed on <u>Jul</u>	<u>y 14, 2000;</u>		
as United States	Application Number of PCT Internet	ional Application Number <u>09/617,116:</u> a	
was amended on	(it applicab	le).	nd
I hereby state that I have a		of the above identified specification, inc.	luding the claims, as
		to patentability as defined in 37 C.F.R. 6	
I hereby claim foreign pricinventor's certificate, or § United States listed below	arity benefits under 35 U.S.C. § 119(a 365(a) of any PCT int mational appli	a)-(d) or § 365(b) of any foreign application, which designated at least one conforcign application for patent or inventor; pplication on which priority is claimed.	ion(s) for natent or
Prior Foreign Application(
	ਾ: -		Priority Claimed
(Application No.)	(Co intry)	(Day/Month/Year Filed)	□Yes □No
(Application No.)	(Country)	(Day/Month/Year Filed)	□ Yes □ No
I hereby claim the benefit u	inder 35 U.S.C. § 119(3) of any Unite	. d States provisional application listed be	
60/144,074		- vinites provisional application listed be	low.
(Application No.)	July 16, 1995 (Piling Date)		
(Application No.)	(Filing Dato)		
his application is not disclo paragraph of 35 U.S.C. 6.11	sed in the prior United States or PCT	tates application(s), or under § 365(c) of pw and, insofar as the subject matter of exinternational application in the manner prinformation that is material to patentabile prior application and the national or PC.	ach of the claims of provided by the first
Application No.)	(Filin-; Date)	(Status - patented, pendin	ng, abandoned)
Application No.)	(Filin; Date)	(Starus - patented, pendin	g, abandoned)



Appl. No. 09/617,116 Docket No. 0609,4830001/KRM/SJB

Send Correspondence to:

Sterne, Kessler, Goldstein & Fox P.L.L.C. 1106 New York Avenue, N.W., Suite 600 Washington, D.C. 20005-3934

Direct Telephone Calls to:

(202) 371-2600

I hereby declare that all statements made hereir, of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sets or first inventor	Manish AGHI	
Signature of sole or first inventer	Mest	8/27/00
Residence	19 Netherlands Road, Approment #2 Brookline, MA 02445	
Citizenship	U.S.A.	
Post Office Address	Sume as above	
Full name of second inventor	Christof M. KRAMM	
Signature of second inventor		Date.
Residence	Jahnstr, 65 40215 Duesseldorf Germany	
Citizenship	Germany	
Post Office Address	Sainc as above	
Full name of third inventor	Xandra O. BREAKEFIELD	
Signature of third inventor		Dase
Residence	127 Homer Street Newton, MA 02459	
Citizenship	U.5.A.	
Post Office Address	Same as above	

Declaration for Patent Application

As a below named inventor, I hereby declare that:

Docket Number: 0609.4830001/KRM/SJB

My residence, post office address and citizenship are as stated pelow next to m

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled Folylpolyglutamyl Synthetase Gene Transfer To Enhance Antifolate Drug Sensitivity, the specification of which is attached hereto unless the following box is checked:

⊠	was filed on July 14, 200 as United States Applica was amended on	00; Ition Number or PCT International A	Application Number <u>09/617,116</u> ; a	nd	
I hereb	by state that I have reviewed ed by any amendment refer	d and understand the contents of the rred to above.	e above identified specification, inc	luding the clai	ims, as
I ackno	owledge the duty to disclos	e information that is material to pat	entability as defined in 37 C.F.R. §	1.56.	
invente	or's certificate, or § 365(a) I States listed below, and ha	enefits under 35 U.S.C. § 119(a)-(d) of any PCT international application ave also identified below any foreign a filing date before that of the application	n, which designated at least one co in application for patent or inventor	untry other that	an tne
Prior F	Foreign Application(s)			Priority	Claimed
		(Country)		□ Yes	□ No
(Appli	ication No.)	(Country)	(Day/Month/Year Filed)		
			· · · · · · · · · · · · · · · · · · ·	□ Yes	□ No
(Appli	ication No.)	(Country)	(Day/Month/Year Filed)		
I herel	by claim the benefit under	35 U.S.C. § 119(e) of any United S	tates provisional application listed	below.	
60/14	4 074	July 16, 1999			
	ication No.)	(Filing Date)			
(Appl	ication No.)	(Filing Date)			
intern this ap parag C.F.R	ational application designa pplication is not disclosed in traph of 35 U.S.C. 8 112 J	35 U.S.C. § 120 of any United State ting the United States, listed below in the prior United States or PCT in acknowledge the duty to disclose in able between the filing date of the pa	and, insofar as the subject matter of ternational application in the mann formation that is material to patent	of each of the co er provided by ability as defir	ned in 37
(Appl	lication No.)	(Filing Date)	(Status - patented, pe	nding, abando	ned)
(App	lication No.)	(Filing Date)	(Status - patented, pe	nding, abando	ned)

Appl. No. 09/617,116 Docket No. 0609.4830001/KRM/SJB

Send Correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 New York Avenue, N.W., Suite 600 Washington, D.C. 20005-3934

Direct Telephone Calls to:

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	Manish AGHI		
Signature of sole or first inventor			Date
Residence	19 Netherlands Road, Apartment #2 Brookline, MA 02445		
Citizenship	U.S.A.		· -
Post Office Address	Same as above		-
Full name of second inventor	Christof M. KRAMM		
Signature of second inventor	Christof Yamm	Otober 7, 2000	Date
Residence	Jahnstr. 65 40215 Duesseldorf Germany	,	
Citizenship	Germany	•	
Post Office Address	Same as above		
Full name of third inventor	Xandra O. BREAKEFIELD		
Signature of third inventor			Date
Residence	127 Homer Street Newton, MA 02459		
Citizenship	U.S.A.		
Post Office Address	Same as above		

Declaration for Patent Application

Docket Number: 0609.4830001/KRM/SJB

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to mame

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled Folylpolyglutamyl Synthetase Gene Transfer To Enhance Antifolate Drug Sensitivity, the specification of which is attached hereto unless the following box is checked:

Folylpolyglutamyl Synthe hereto unless the following	g box is checked:	e Diug Schshivity, die speemeatie	n or which is accorda
was filed on <u>July</u> as United States was amended on	14, 2000; Application Number or PCT Internationa (if applicable).	al Application Number <u>09/617,116</u>	and
I hereby state that I have r amended by any amendme	reviewed and understand the contents of tent referred to above.	he above identified specification, i	ncluding the claims, as
I acknowledge the duty to	disclose information that is material to p	patentability as defined in 37 C.F.R	. § 1.56.
inventor's certificate, or §	ority benefits under 35 U.S.C. § 119(a)-(365(a) of any PCT international applicat v, and have also identified below any fore having a filing date before that of the app	tion, which designated at least one gign application for patent or invention	country other than the tor's certificate, or PCT
Prior Foreign Application	n(s)		Priority Claimed
(Application No.)	(Country)	(Day/Month/Year Filed)	□ Yes □ No
		·	□ Yes □ No
(Application No.)	(Country)	(Day/Month/Year Filed)	
I hereby claim the benefit	t under 35 U.S.C. § 119(e) of any United	States provisional application liste	d below.
60/144,074	July 16, 1999		•
(Application No.)	(Filing Date)		
(Application No.)	(Filing Date)		
international application this application is not dis	t under 35 U.S.C. § 120 of any United St designating the United States, listed belo closed in the prior United States or PCT § 112, I acknowledge the duty to disclose the available between the filing date of the	w and, insofar as the subject matter international application in the ma- information that is material to pate	nner provided by the first ntability as defined in 37
(Application No.)	(Filing Date)	(Status - patented,	pending, abandoned)
(Application No.)	(Filing Date)	(Status - patented,	pending, abandoned)

Appl. No. 09/617,116 Docket No. 0609.4830001/KRM/SJB

Send Correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 New York Avenue, N.W., Suite 600 Washington, D.C. 20005-3934


Direct Telephone Calls to:

PAUSERS\SBROTMAN0609M83-1\doclaration

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	Manish AGHI	
Signature of sole or first inventor		Date
Residence	19 Netherlands Road, Apartment #2 Brookline, MA 02445	
Citizenship	U.S.A.	
Post Office Address	Same as above	
Full name of second inventor	Christof M. KRAMM	en per en
Signature of second inventor		Date
Residence	Jahnstr. 65 40215 Duesseldorf Germany	
Citizenship	Germany	
Post Office Address	Same as above	
Full name of third inventor	Xandra O. BREAKEFIELD	
Signature of third inventor	reatified	Sept 20, 2000
Residence	127 Homer Street Newton, MA 02459	
Citizenship	U.S.A.	
Post Office Address	Same as above	



Certificate Under 37 C.F.R. § 3.73(b)

Applica	nt/Patent Owner: Manish	AGHI, Christof M.	KRAMM, and Xandra O. BREAKEFIELD
Applica	ation No./Patent No.:	09/617,116	Filed/Issue Date: July 14, 2000
Entitled	: Folylpolyglutamyl Syn	thetase Gene Tran	sfer to Enhance Antifolate Drug Sensitivity
	The General Hospital C	orporation	, a <u>Corporation</u>
	(Name of Assignee)		(Type of Assignee, e.g., corporation, partnership, university, government agency,etc.)
states th	nat it is:		
1. [X]	the assignee of the entire	e right, title, and inte	rest, or
2. []	an assignee of an undivi	ded part interest	
in the p	atent application/patent ic	lentified above by vi	rtue of either:
A. [X]			atent application/patent identified above. The assignment office at Reel, Frame, or for which a copy
OR	dicteor is attached.		
B.[]	A chain of title from the assignee as shown below		atent application/patent identified above to the current
		was recorded in the	Patent and Trademark Office at, or for which a copy thereof is attached.
	2. From:	To:	
	The document	was recorded in the	Patent and Trademark Office at, or for which a copy thereof is attached.
	The document	was recorded in the	Patent and Trademark Office at, or for which a copy thereof is attached.
	[] Additional documen	ts in the chain of titl	e are listed on a supplemental sheet.
[X] Co	[NOTE: A separate cop document) must be subr	y (i.e., the original a nitted to Assignmen	chain of title are attached. ssignment document or a true copy of the original t Division in accordance with 37 CFR Part 3, if ds of the PTO. See MPEP 302-302.8]
The unc	lersigned (whose title is s	upplied below) is en	powered to act on behalf of the assignee.
Date: _	10/31/00	>	
Name: _	The General H	ospital Corporation	
Title: _	Associate Director, Corp	porate Sponsored Re	search and Licensing
Signatu	re:		·
P:\USERS\po SKGF Rev.3.	domally\KRM\0609\3.73(b)cert /31/00 mac		

DO NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: Manish AGHI, Christof M. KRAMM, and Xandra O. BREAKEFIELD, the undersigned inventors hereby sell and assign to The General Hospital Corporation (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☐ for the United States of America (as defined in 35 U.S.C. § 100), ☐ and throughout the world,

(a) in the invention known as Folylpolyglutamyl Synthetase Gene Transfer To Enhance Antifolate Drug Sensitivity for which application for patent in the United States of America has been executed by the undersigned on 8 27 50 (also known as United States Application No. 09/617,116, filed July 14, 2000, in any and all applications thereon, in any and all Letters Patent(s) therefor, and



- (b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; Samuel L. Fox, Esquire, Registration No. 30,353; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire,

Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; Raz E. Fleshner, Esquire, Registration No. 34,331; John M. Covert, Esquire, Registration No. 38,759; and Linda E. Alcorn, Esquire, Registration No. 39,588; all of Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

X	Date: 8 27 00	Signature of Inventor:	Manish AGM
	Date:	Signature of Inventor:	Christof M. KRAMM
	Date:	Signature of Inventor: _	Xandra O. BREAKEFIELD

P:\USERS\SBROTMAN\0609\483-1\nonprovassignment

DO NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: Manish AGHI, Christof M. KRAMM, and Xandra O. BREAKEFIELD, the undersigned inventors hereby sell and assign to The General Hospital Corporation (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es)

✓ for the United States of America (as defined in 35 U.S.C. § 100),

✓ and throughout the world,

- (a) in the invention known as Folylpolyglutamyl Synthetase Gene Transfer To Enhance Antifolate Drug Sensitivity for which application for patent in the United States of America has been executed by the undersigned on October 7, 2000 (also known as United States Application No. 09/617,116, filed July 14, 2000, in any and all applications thereon, in any and all Letters Patent(s) therefor, and
- (b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; Samuel L. Fox, Esquire, Registration No. 30,353; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire,

Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; Raz E. Fleshner, Esquire, Registration No. 34,331; John M. Covert, Esquire, Registration No. 38,759; and Linda E. Alcorn, Esquire, Registration No. 39,588; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

	Date:		Signature of Inventor:	Manish AGHI	
X	Date:	Odder 7,2000	Signature of Inventor:	Christof M. KRAMM	\
	Date:		Signature of Inventor:	Xandra O. BREAKEFIELD	

P:\USERS\SBROTMAN\0609\483-1\nonprovassignment

DO NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: Manish AGHI, Christof M. KRAMM, and Xandra O. BREAKEFIELD, the undersigned inventors hereby sell and assign to The General Hospital Corporation (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es)

✓ for the United States of America (as defined in 35 U.S.C. § 100),

✓ and throughout the world,

(a) in the invention known as Folylpolyglutamyl Synthetase Gene Transfer To Enhance Antifolate Drug Sensitivity for which application for patent in the United States of America has been executed by the undersigned on 9/20/00 (also known as United States Application No. 09/617.116, filed July 14, 2000, in any and all applications thereon, in any and all Letters Patent(s) therefor, and



- (b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; Samuel L. Fox, Esquire, Registration No. 30,353; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire,

Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; Raz E. Fleshner, Esquire, Registration No. 34,331; John M. Covert, Esquire, Registration No. 38,759; and Linda E. Alcom, Esquire, Registration No. 39,588; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

	Date:	Signature of Inventor:
	Date:	Signature of Inventor:Christof M. KRAMM
X	Date: <u>Sept 20, 2000</u>	Signature of Inventor: Xardia Briake Justine Xandra O. BREAKEFIELD

P:\USERS\SBROTMAN\0609\483-1\nonprovassignment



The General Hospital Corporation, a corporation of Massachusetts, having a principal place of business at Fruit Street, Boston, Massachusetts 02114, is assignee of the entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment to the Assignee executed on 08/27/00, 10/7/00, 9/20/00 of an invention known as Folylpolyglutamyl Synthetase Gene Transfer To Enhance Antifolate Drug Sensitivity (Attorney Docket No. 0609.4830001/JAG/KRM), which is disclosed and claimed in a patent application of the same title by the inventors Manish AGHI, Christof M. KRAMM, and Xandra O. BREAKEFIELD (said application filed on July 14, 2000 at the U.S. Patent and Trademark Office, having Application Number 09/617,116).

The Assignee hereby appoints the following U.S. attorneys to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith: Robert Greene Sterne, Esq., Reg. No. 28,912; Edward J. Kessler, Esq., Reg. No. 25,688; Jorge A. Goldstein, Esq., Reg. No. 29,021; Samuel L. Fox, Esq., Reg. No. 30,353; David K.S. Cornwell, Esq., Reg. No. 31,944; Robert W. Esmond, Esq., Reg. No. 32,893; Tracy-Gene G. Durkin, Esq., Reg. No. 32,831; Michael A. Cimbala, Esq., Reg. No. 33,851; Michael B. Ray, Esq., Reg. No. 33,997; Robert E. Sokohl, Esq., Reg. No. 36,013; Eric K. Steffe, Esq., Reg. No. 36,688, Michael Q. Lee, Esq., Reg. No. 35,239; Steven R. Ludwig, Esq., Reg. No. 36,203; John M. Covert, Esq., Reg. No. 38,759; and Linda E. Alcorn, Esq., Reg. No. 39,588. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005-3934 U.S.A.

Direct phone calls to 202-371-2600.

FOR:	The General Hospital Corporation
SIGNATURE:	
BY:	David J. Glass, Ph.D.
TITLE:	Associate Director, Corporate Sponsored Research and Licensing
DATE:	10/31/00